Semaglutide (Wegovy, approved June 2021) and tirzepatide (Zepbound, approved November 2023) represent the current standard of care for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity [7][8]
This is completely normal for this product and does not indicate damage, contamination, or reduced quality
Gastrointestinal Mild transient diarrhea
When NNMT is too active, your NAD+ levels drop your metabolism slows, fat burning gets harder, and your body stores more fat instead of using it for energy
The goal discussed in clinical settings is to support the bodys fat-metabolism support, which decline naturally with age
However, in one year-long phase 3 trial involving 2,000 severely obese patients, disappointing results were seen in the axokine-treated group [75]